Surrogate and Sentinal Technologies to Monitor Stability of Cancer Phosphoprotein
Surrogate and Sentinal Technologies to Monitor Stability of Cancer Phosphoprotein
批准号:
7846929
负责人:
Lance Allen Liotta
金额:
$1.08万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-05 至 2009-10-31
关键词:
AddressAmbulatory Care FacilitiesBiological AssayBiological PreservationBiopsyBiopsy SpecimenBuffersCell Cycle RegulationChemistryClinicClinicalCollectionCommunity HospitalsCore BiopsyDataDevelopmentDiseaseExcisionFine needle aspiration biopsyFoundationsFreezingGatekeepingGoalsGrowth FactorGuidelinesHalf-LifeHospitalsHourHumanHypoxiaInflammatoryMalignant NeoplasmsMeasurementMeasuresMicroarray AnalysisMicrodissectionMolecularMolecular AnalysisMolecular ProfilingMonitorMorphologyNeedlesOne-Step dentin bonding systemOperating RoomsOperative Surgical ProceduresOutcomePathogenesisPathway interactionsPatientsPeptidesPerformancePhasePhosphoproteinsPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesProcessProtein MicrochipsProteinsProteomicsProtocols documentationQualifyingRecording of previous eventsSentinelSeriesShippingShipsSignal PathwaySignal TransductionSolidSolutionsSpecimenStimulation of Cell ProliferationStressSurrogate EndpointSurrogate MarkersTechnologyTemperatureTestingTimeTissue BankingTissue BanksTissue HarvestingTissue PreservationTissue ProcurementsTissue SampleTissuesbasecancer therapyclinical Diagnosishuman tissuelaser capture microdissectionmultidisciplinarynanoparticlenew technologynovelphosphatase inhibitorphosphatase-1 kinasequality assuranceresponsetherapeutic targettime intervaltissue processingtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The phosphorylation, or activation state of kinase-driven signal networks embodies information concerning disease pathogenesis and the ongoing state of kinase associated therapeutic targets. Profiling the tumor phosphoproteome using human tumor biopsy specimens is a crucial component of the perceived upcoming revolution of individualized cancer therapy. A critical unmet need addressed by this application is tissue phosphoprotein stability data, standardized protocols, and novel technologies which can be used in the real world clinical setting (e.g. operating room, outpatient clinic biopsy, radiological suite needle aspiration) for seamless collection, immediate preservation, and real time stability monitoring of phosphoproteins. Our multidisciplinary team has previously developed Laser Capture Microdissection (LCM) and reverse phase protein microarray (RPA) technologies to conduct phosphoproteomic analysis of the tissue microenvironment. We will standardize the RPA technology to simultaneously measure at least 100 known phosphoprotein endpoints with high precision and sensitivity in a human core needle biopsy or fine needle aspirate. This technology will be used to collect previously unknown quantitative information about the tissue half-life of phosphoproteins representing a wide range of signaling pathways, cellular compartments and phosphorylated residues over time zero to 48 hours. These data will become the basis to identify a subset of highly representative and most-labile endogenous phosphoproteins which can be employed as novel surrogate quantitative markers of tissue preservation and phosphoprotein stability. We will employ this stability data and novel surrogate endpoints technology to propose definitive quantitative guidelines for tissue perishability limits. We will create exogenous phosphoprotein sentinel nanoparticles to record the processing history of the specimen for ongoing Quality Assurance. The RPA, surrogate markers, and sentinel technology will be used to rank candidate preservative solutions that stabilize kinases, phosphatases, and phosphoproteins for 24-48 hr at room temperature. The desired outcome will be a complete standardized technology kit which can be employed for routine clinical collection, shipping, early warning of perished tissue, and real time monitoring of tissue phosphoproteins for molecular profiling.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.
肺癌和乳腺癌脑转移的蛋白质通路激活图谱揭示了器官类型特异性药物靶点激活。
DOI:
10.1021/pr200065t
发表时间:
2011-07-01
期刊:
Journal of proteome research
影响因子:
4.4
作者:
[Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin EF 3rd, Wulfkuhle JD]
通讯作者:
Wulfkuhle JD
DOI:
10.1016/j.molonc.2010.09.003
发表时间:
2010-12
期刊:
Molecular oncology
影响因子:
6.6
作者:
[Mueller C, Liotta LA, Espina V]
通讯作者:
Espina V
DOI:
10.1080/14789450.2021.1984886
发表时间:
2021-10
期刊:
EXPERT REVIEW OF PROTEOMICS
影响因子:
3.4
作者:
[Liotta, Lance A., Pappalardo, Philip A., Carpino, Alan, Haymond, Amanda, Howard, Marissa, Espina, Virginia, Wulfkuhle, Julie, Petricoin, Emanuel]
通讯作者:
Petricoin, Emanuel
Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.
多重蛋白质信号通路图谱可识别对新辅助治疗有反应的直肠癌患者。
DOI:
10.1016/j.clcc.2012.05.003
发表时间:
2012
期刊:
Clinical colorectal cancer
影响因子:
3.4
作者:
[Mammano,Enzo, Galdi,Francesca, Pierobon,Mariaelena, Tessari,Emanuela, Deng,Jianghong, Pucciarelli,Salvatore, Agostini,Marco, DeMarchi,Francesco, Canzonieri,Vincenzo, DePaoli,Antonino, Belluco,Claudio, Liotta,Lance, Petricoin,Emanuel, Pilati]
通讯作者:
Pilati
DOI:
10.18632/oncotarget.17579
发表时间:
2017-07-11
期刊:
Oncotarget
影响因子:
--
作者:
[Spreafico F, Bongarzone I, Pizzamiglio S, Magni R, Taverna E, De Bortoli M, Ciniselli CM, Barzanò E, Biassoni V, Luchini A, Liotta LA, Zhou W, Signore M, Verderio P, Massimino M]
通讯作者:
Massimino M
共 8 条
Targeting Rab6-km23-1-mediated compartmentalized trafficking as a novel therapeutic approach to Alzheimers Disease
-
批准号:9756263
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2018
-
负责人:Lance Allen Liotta
-
依托单位:
Protein painting identifies therapeutic targets at protein-protein interfaces
-
批准号:9392299
-
项目类别:
-
资助金额:$9.45万
-
财政年份:2016
-
负责人:Lance Allen Liotta
-
依托单位:
Protein painting identifies therapeutic targets at protein-protein interfaces
-
批准号:9338200
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2016
-
负责人:Lance Allen Liotta
-
依托单位:
Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation
-
批准号:9085212
-
项目类别:
-
资助金额:$56.88万
-
财政年份:2015
-
负责人:Lance Allen Liotta
-
依托单位:
Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation
-
批准号:8944833
-
项目类别:
-
资助金额:$59.52万
-
财政年份:2015
-
负责人:Lance Allen Liotta
-
依托单位:
Protein Painting reveals hidden protein-protein interaction domains
-
批准号:8728792
-
项目类别:
-
资助金额:$23.73万
-
财政年份:2013
-
负责人:Lance Allen Liotta
-
依托单位:
Protein Painting reveals hidden protein-protein interaction domains
-
批准号:8547427
-
项目类别:
-
资助金额:$24.47万
-
财政年份:2013
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8548317
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8433072
-
项目类别:
-
资助金额:$38.04万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8723137
-
项目类别:
-
资助金额:$35.76万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8311650
-
项目类别:
-
资助金额:$30.95万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8504815
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8079819
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
A non-invasive nanotechnology-based skin patch for multiplexed diagnostics
-
批准号:8265831
-
项目类别:
-
资助金额:$19.64万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
A non-invasive nanotechnology-based skin patch for multiplexed diagnostics
-
批准号:8092239
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7847757
-
项目类别:
-
资助金额:$1.06万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers i
-
批准号:7586530
-
项目类别:
-
资助金额:$14.92万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers i
-
批准号:7935029
-
项目类别:
-
资助金额:$20.04万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7680019
-
项目类别:
-
资助金额:$19.28万
-
财政年份:2008
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7451923
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2008
-
负责人:Lance Allen Liotta
-
依托单位: